Recent research in science establishes a direct relation between human gut and skin. Several species of live microbes inhabit the human skin and intestines which far outnumbers the mammalian cells in the human body. Research interest of Nextgen scientists is focused on beneficially harnessing this microbial population to address skin disorders like acne, rosacea, eczema, premature aging, and skin cancer which are established to be a result of skin-microbiome dysbiosis. This volume highlights evidence-based endeavours of the scientific community in this sector. Currently there is no concrete literature which gives a detailed vision on the relationship between gut microbiota and skin related disorders. This volume is an attempt to put together available data in the area and demonstrate usefulness of probiotics as a new therapeutic option for management of these skin diseases which currently show poor prognosis, high cost of treatment and compromised quality of life of the patient.
Dr Indu Pal Kaur is a Professor of Pharmaceutics and currently the Chairperson at University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, India with more than 25 years of teaching and research experience. Her research forte is enhancing bioperformance of drugs including small and large biomolecules viz. probiotics using active-tailored delivery systems. Emphasis of her work lies on Industrial and clinical translation of her work as evidenced by four technologies transferred by her group to the Industry. She has been granted ten (10) patents and has filed 19 more patent applications. She has 145 high impact publications, 21 book chapters, 4 books and 4 Journal special issues to her credit. She has delivered 50 invited talks and more than 150 presentations have been made by her research group, with 30 being adjudged as best presentations. She is on the editorial and Review Board of more than 50 journals. She has received funding to the tune of 75 million INR from Government agencies and has a couple of Industrial consultancies amounting to 15 million INR. Prof Kaur was awarded the very prestigious 'Fulbright- Fellowship (FNAPE)' by USA, and she was a visiting faculty at Rutgers State University, New Jersey in 2017-18. Organizers of Pharmaceutical Producers of India (OPPI) bestowed upon her 'The best Women Scientist Award-2018.' Her novel ideas and technologies received BRIC Technology Exposition Award, consecutively in 2019 and 2020.
Dr. Kavita Beri is a Board-Certified Physician and Scientist in the field of Regenerative Medicine. Dr. Beri is the Founder of BE MIND BODY SKIN, a Next Generation Integrative Aesthetics and Wellness Spa in Ocean New Jersey. She is also the founder of a newly launched all-natural cosmetic line, KYVTA, that is based on the concept of 'Vibrational Cosmetics.' She has published several scientific articles and presented her research work both nationally and internationally. She is also a visiting scientist at the Center for Dermal research and an Adjunct Professor of Biomedical Engineering, Rutgers State University, USA. Dr. Beri is an Editorial Advisor & Dermatology Social Media Editor for the Future Science Journal. She is a member of the scientific advisory board for TecknoScience Publisher H&PC Today Magazine and a reviewer for several other journals in regenerative medicine, biotechnology, dermatology and cosmetics. Her passion is in mind, body and skin regeneration and its connection through the microbiome. She is a certified yoga teacher, training new yoga instructors on philosophy of Yoga and the Mind Body and Energy connection. She has a deep interest in applications of Vibrational Medicine and how it can be connected to Anti-Aging Aesthetics by connecting the concept of microbiome-host symbiosis.
Dr Parneet Kaur Deol, is presently working as Assistant Professor at G.H.G. Khalsa College of Pharmacy Gurusar Sadhar Ludhiana, Punjab, India. She has more than 10 years of experience in probiotic research and has published her work in highly reputed peer reviewed international journals. She has 21 international publications to her credit with cumulative impact of more than 50. She has filed one Indian patent application. She has co-edited a special issue for 'Current Pharmaceutical Design' with Prof. Indu Pal Kaur in the year 2019. Dr Deol has presented her work at various national and international platforms. She was awarded with the 'Dr. Harpal Singh Buttar and Mrs. Harinder Kaur Buttar Award of Excellence in Pharmaceutical Sciences' in the year 2016 and Mekaster Young Scientist Award in 2018 for her research work. Recently she fetched two research projects from Department of Science and Technology-Science and Engineering Research Board (DST-SERB), New Delhi worth 65 lakh.
Dr Simarjot Kaur Sandhu, is presently working as analytical chemist at Taro Pharmaceutical Industries Ltd. Brampton, Ontario, Canada. She has done her doctorate from University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. Her area of research lies in improving the bioprofile of phytopharmaceuticals and probiotics by encapsulating them within nanoparticles. She has published 6 International publications and has filed two India Patent Applications and one European and one US patent application out of her PhD work.
Recent research in science establishes a direct relation between human gut and skin. Several species of live microbes inhabit the human skin and intestines which far outnumbers the mammalian cells in the human body. Research interest of Nextgen scientists is focused on beneficially harnessing this microbial population to address skin disorders like acne, rosacea, eczema, premature aging, and skin cancer which are established to be a result of skin-microbiome dysbiosis. This volume highlights evidence-based endeavours of the scientific community in this sector. Currently there is no concrete literature which gives a detailed vision on the relationship between gut microbiota and skin related disorders. This volume is an attempt to put together available data in the area and demonstrate usefulness of probiotics as a new therapeutic option for management of these skin diseases which currently show poor prognosis, high cost of treatment and compromised quality of life of the patient.